#RLMD hashtag - Bluesky

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update Relmada Therapeutics (Nasdaq: RLMD) reported strong Phase 2 NDV-01 data and completed a $160 million PIPE financing to fund development through 2029. Key clinical results showed a 95% CR rate at any time and a 76% durable CR at 12 months in high‑risk NMIBC.The company is aligned with the FDA on two registrational pathways and plans to initiate the Phase 3 RESCUE program in mid‑2026, with IND clearance targeted the same period.

2 weeks ago

#RLMD Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing Relmada Therapeutics (Nasdaq: RLMD) announced an oversubscribed private placement expected to raise approximately $160.0 million gross, before placement agent fees and offering expenses. The financing consists of 29,474,569 common shares at $4.75 and 4,210,527 pre-funded warrants at $4.749.The pre-funded warrants carry a $0.001 exercise price. Closing is expected on or about March 11, 2026, subject to customary conditions. Proceeds will be used for working capital and advancing R&D. The company agreed to file resale registration rights.

3 weeks ago

#RLMD Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer Relmada Therapeutics (Nasdaq: RLMD) reported 12-month Phase 2 interim data for NDV-01 in high-risk non-muscle invasive bladder cancer. The study showed a 12-month complete response (CR) rate of 76% overall and 80% in BCG-unresponsive patients, with 95% and 94% CR rates at any time, respectively. No patients progressed to muscle-invasive disease or required radical cystectomy. No ≥ Grade 3 treatment-related adverse events or treatment discontinuations were reported. Relmada plans IND clearance and initiation of the Phase 3 RESCUE program in mid-2026, with initial Phase 3 3-month readouts expected by year-end 2026.

3 weeks ago

#RLMD Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications Relmada Therapeutics (Nasdaq: RLMD) announced FDA written feedback supporting its registrational development pathway for NDV-01 in two separate non-muscle invasive bladder cancer (NMIBC) indications.The FDA indicated a single-arm, open-label registrational trial is appropriate for 2nd-line refractory, high-grade BCG-unresponsive NMIBC with carcinoma in situ (CIS). The agency also provided supportive written feedback for a single randomized-to-observation registrational trial in intermediate-risk NMIBC in the adjuvant setting. Relmada expects to initiate both Phase 3 registrational trials in 1H 2026.

2 months ago

#RLMD Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

3 months ago

JUST IN: ( NASDAQ: #RLMD ) Relmada Therapeutics Inc. (NASDAQ: RLMD) is a Stock Spotlight on 12/30

0 0 0 0

4 months ago

NEWS: ( NASDAQ: #RLMD ) Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

0 0 0 0

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation of gemcitabine/docetaxel (Gem/Doce), into Phase 3 studies in

4 months ago

#RLMD Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

4 months ago

JUST IN: ( NASDAQ: #RLMD ) Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

0 0 0 0

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates Relmada Therapeutics (Nasdaq: RLMD) reported Q3 2025 results and pipeline updates on Nov 13, 2025, highlighting a 92% complete response rate (anytime) at 9-month follow-up for NDV-01 in NMIBC and favorable safety.The company secured FDA alignment on Phase 3 pathways with two potential registrational routes (high-risk 2nd-line BCG-unresponsive single-arm and intermediate-risk adjuvant randomized trial) and expects to initiate studies in H1 2026. Relmada closed an underwritten offering on Nov 5, 2025 providing approximately $100M gross proceeds and said available cash including offering proceeds should support operations into 2028.

4 months ago

#RLMD Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

4 months ago

BREAKING NEWS: ( NASDAQ: #RLMD ) RLMD - Historical Price Movements Surrounding Earnings

0 0 0 0

4 months ago

Just In: ( NASDAQ: #RLMD ) RLMD - Historical Earnings Price Analysis

0 0 0 0

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Relmada Therapeutics (NASDAQ: RLMD) priced an underwritten offering to raise approximately $100 million in gross proceeds by selling 40,142,000 common shares and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 5,315,000 common shares.Common shares priced at $2.20 each; pre-funded warrants priced at $2.199 each (reflecting a $0.001 exercise price). The offering is expected to close on November 5, 2025, subject to customary closing conditions. Institutional investors participated and Jefferies, Leerink Partners and Mizuho acted as book-runners. Net proceeds will fund working capital, clinical studies, systems and potential strategic investments.

4 months ago

#RLMD Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

Relmada Issues Mid-Year CEO Letter to Shareholders Relmada Therapeutics (NASDAQ: RLMD) has issued a mid-year CEO letter highlighting significant developments in 2025. The company has expanded its portfolio with two Phase 2 candidates: NDV-01 for non-muscle invasive bladder cancer (NMIBC) and Sepranolone for compulsivity disorders.NDV-01 demonstrated impressive 91% complete response rate in Phase 2 six-month follow-up data. The company plans to initiate Phase 3 trials in H1 2026. To strengthen the program, Relmada appointed Dr. Raj S. Pruthi as CMO-Oncology and Dr. Yair Lotan as Clinical Advisory Board Chair.For Sepranolone, following positive proof-of-concept data in Tourette's syndrome, Relmada plans to begin Phase 2 trials for Prader-Willi Syndrome in H1 2026, targeting a population of 350,000-400,000 patients worldwide.

6 months ago

#RLMD Relmada Issues Mid-Year CEO Letter to Shareholders

www.stocktitan.net/news/RLMD/relmada-issues...

0 0 0 0

@smcapstrategist.bsky.social

7 months ago

NEWS: ( NASDAQ: #RLMD ) Morning Market Briefing: Micro-Caps Primed for Breakouts

0 0 0 0

Small Cap Strategist

7 months ago

Leading Indicators, Thursday August 21, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Thu Aug 21st - #USIO #TSP #RLMD #NEOV #MOVE #LIMN #INVE #GREE #EM #CRGX #ACNT #VET #TLYS #DHX #CLB #ASIX - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC Relmada Therapeutics (NASDAQ:RLMD) reported significant progress in its Q2 2025 financial results and clinical developments. The company announced impressive 6-month follow-up data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), showing a 91% overall response rate with favorable safety profiles. No patients progressed to muscle invasive disease or required radical cystectomy.Financial results showed reduced losses, with Q2 2025 net loss at $9.9 million ($0.30 per share) compared to $17.8 million in Q2 2024. The company maintained $20.6 million in cash and equivalents as of June 30, 2025. Relmada plans to initiate a Phase 3 registration trial for NDV-01 in 1H 2026 and advance sepranolone into Phase 2 studies for Prader-Willi syndrome.

7 months ago

#RLMD Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Relmada Therapeutics (RLMD) reported Q1 2025 financial results and provided pipeline updates. The company highlighted positive Phase 2 proof-of-concept data for NDV-01, showing a 90% overall response rate in non-muscle invasive bladder cancer patients. Key financial metrics include: net loss of $17.5 million ($0.58/share), R&D expenses of $11.9 million, and cash position of $27.1 million. NDV-01, a sustained-release intravesical formulation, demonstrated 89% high-grade recurrence-free survival in papillary disease and 100% complete response in carcinoma in situ. The company plans to initiate a Phase 3 trial for NDV-01 and a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026.

10 months ago

#RLMD Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial New Phase 2 data reveals NDV-01's strong efficacy in bladder cancer treatment, with 90% disease-free status and favorable safety profile. See full results.

11 months ago

#RLMD Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend with average directional index, Wed Apr 23rd - #AREN #OKYO #GAUZ #VBTX #SIGA #RLMD #PESI #NEON #SNOA #JANX #IRIX #FHTX #EDIT #DRCT #CNCK #AMLX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Relmada Cuts Losses by 25%: Key Pipeline Programs Hit Critical Phase in 2025 Net loss improves to $18.6M as Relmada advances NDV-01 and sepranolone programs. Phase 2 data expected in 2025, with pivotal trials planned. See development timeline.

1 year ago

#RLMD Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

Game-Changing Cancer Drug: Relmada's New Treatment Lasts 10 Days vs Hours Exclusive license for innovative bladder cancer therapy targeting 600k+ patients. Superior 10-day sustained release could transform treatment. Full analysis inside.

1 year ago

#RLMD Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

Groundbreaking Tourette Treatment Shows 69% QoL Improvement in Clinical Trial - Relmada's Latest Acquisition Relmada acquires Sepranolone, showing 28% tic reduction and major QoL improvements in Phase 2a Tourette syndrome trial. Zero CNS side effects reported. Phase 2b ready.

1 year ago

#RLMD Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

Relmada Therapeutics Halts Major Phase 3 Trials, Explores Strategic Sale Options Relmada discontinues key REL-1017 Phase 3 studies following monitoring committee review, initiates strategic alternatives exploration including potential company sale.

1 year ago

#RLMD Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

#StockMarket #stocks #news

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

1 year ago

#RLMD Relmada Therapeutics to Present at Jefferies London Healthcare Conference

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0